BIMERVAX® has also obtained the approval of the European Commission to be marketed

After the European Medicines Agency (EMA) gave its positive opinion on BIMERVAX®, the European Commission has also given its approval on the same day, 30 th March. Therefore, HIPRA’s vaccine against COVID-19 now has the green light to be marketed in the European Union. BIMERVAX® is indicated as a booster dose in people over 16 years of age who have been previously vaccinated with an mRNA vaccine. It's a bivalent adjuvanted vaccine containing a recombinant protein based on the Beta and Alpha variants of SARS-CoV-2.

The release as fetched from its publisher. hipra.com ↗